ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) ...

"We've all had our vaccinations. And we continue to since we've lost dad," says John Cross's daughter. "But now you start to ...

NHS pharmacist John Cross ends life after Covid vaccine complications; denied compensation by VDPS after delays of over two ...

How I survived 11 months in Putin’s gulag - EXCLUSIVE INTERVIEW: Vladimir Kara-Murza, one of the faces of Russian opposition ...

British-Russian dissident Vladimir Kara-Murza who was freed from a Siberian penal camp in a historic prisoner swap last month ...

Patisiran for hereditary transthyretin amyloidosis: lesser benefit than vutrisiran In 2023, IQWiG determined an added benefit of vutrisiran over patisiran on the basis of a study. Now the manufacturer ...

Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ROIV stock, giving a Buy rating today. Chris Shibutani has given ...

Immunovant has reported positive results from a trial investigating its monoclonal antibody drug batoclimab in Graves’ ...

The first patient was dosed in the Phase 1b/2a dose escalation trial of KINE-101 study is conducted in Korea in patients with ...

As we have mentioned in our article, “10 Best Penny Stocks to Buy Under $1," the size of the global biotechnology industry ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...